



## Lynparza™ (olaparib) – Product discontinuation

- On August 28, 2018, the [FDA announced](#) the permanent discontinuation of AstraZeneca's [Lynparza \(olaparib\)](#) 50 mg capsules.
  - The discontinuation is not due to any safety, efficacy or quality issues.
  - The planned permanent discontinuation of Lynparza capsules from the U.S. market was August 31, 2018.
  - Lynparza 100 mg and 150 mg [tablets](#) will continue to be available.
- Lynparza capsules and tablets are indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
- In addition, Lynparza tablets are also indicated for the following:
  - Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
  - In patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- Do not substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.